2022
Nanoparticles: The Promising Future of Advanced Diagnosis and Treatment of Neurological Disorders
Nuthalapati P, Asaithambi S, Kumar M, Reddy D. Nanoparticles: The Promising Future of Advanced Diagnosis and Treatment of Neurological Disorders. 2022, 221-234. DOI: 10.1201/9781003157823-18.Peer-Reviewed Original ResearchBlood-brain barrierMultiple sclerosisLimitations of current therapiesNeurological disordersParkinson's diseaseHuntington's diseaseCurrent therapiesClinical studiesTransport drugsNanoparticle strategiesIntroduction of nanotechnologyNoninvasive techniqueNanoparticle technologyDiseaseDrugDamaged nervous tissuePersistent luminescence imagingAdvanced diagnosisEtiologyGold nanoparticlesBrainDisordersNervous tissueDisease treatmentSclerosis
2020
The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
Gross C, Meyer C, Ogale S, Kent M, Wong W. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.29_suppl.89.Peer-Reviewed Original ResearchBiomarker-driven therapiesBiomarker testingEvidence of testingYear of diagnosisQuality cancer careUS cancer patientsLikelihood of testingDe-identified databaseEvidence of receiptEligible ptsOverall survivalAdjusted analysisContemporary cohortMedicaid insuranceRetrospective studyCancer careCancer patientsWorse outcomesCancer clinicHigh riskCommercial insurancePrivate insuranceAdvanced diagnosisTherapyDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply